Valeant plans hostile bid for Allergan

Published



Valeant Pharmaceuticals aims to take its bid for Allergan to the Botox maker’s shareholders after Allegan’s board unanimously rejected its latest offer of about $53 billion.

Valeant said Tuesday that it looked forward to giving shareholders the opportunity “to speak for themselves” after Allergan Chairman and CEO David Pyott said that the offer wasn’t worth discussing in a letter to his Valeant counterpart, Michael Pearson.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.